Clinical Trial Update: The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on milatuzumab for refractory chronic lymphocytic leukemia across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Milatuzumab (milatuzumab)

Snippet

Sponsor: Kaplan Medical Center | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN